Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% YoY. Check out why I ...

Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at ...

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including Snowflake (SNOW) shares seeing continued gains after posting its first-ever ...

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...